Xu-Rong Jiang

Dr. Xu-Rong Jiang is currently a Quality and Technical Director of BioVentures, Global Biologics Operation at AstraZeneca. He is also the Head of Quality for Centus Biotherapeutics Ltd, a joint venture between AstraZeneca and Fujifilm Kyowa Kirin Biologics. In addition, he serves as the Head of Quality for Archigen Biotech Ltd, a joint venture between AstraZeneca and Samsung Biologics. He was an Associate Director in Analytical Biotechnology at MedImmune, and led the Bioassay Development Group for biologics analytical method development for IND filing, GMP testing, technology transfer and process development, and BLA. Prior to MedImmune, Dr. Jiang was a Principal Scientist in Process & Analytical Sciences at Amgen where his group was responsible for development, qualification, validation of potency assays for biologics development. Prior to Amgen, Dr. Jiang was a Senior Scientist at Geron Corporation focusing on gene and cell therapy, high throughput screening, and regenerative medicine with embryonic stem cells. Dr. Jiang received his Ph.D. degree in molecular cell biology from University of London, and his M.D. in hematology from China Medical University. Dr. Jiang has served at various scientific and professional organizations and committees. He is an Associate Director for CASSS, an International Separation Science Society. He has been a member of Scientific Organizing Committee for CASSS Bioassays since 2011. Dr. Jiang has been an organizing committee member for the Cell-based Assay Action Program Committee, American Association for Pharmaceutical Scientists. He has published more than 27 journal papers and is an assignee of three U.S. patents. Dr. Jiang is the President and Chairman of the Board of Directors in the Chinese Biopharmaceutical Association-USA.